Articles On Cynata Therapeutics (ASX:CYP)

Melbourne-based biotechnology company, Cynata Therapeutics, has commenced a Phase 3 clinical trial using its Cymerus stem cell product “CYP-004” to treat patients suffering from osteoarthritis. Osteoarthritis is just one of many ailments th...

Melbourne-based biotechnology company, Cynata Therapeutics, has commenced a Phase 3 clinical trial using its Cymerus stem cell product “CYP-004” to treat patients suffering from osteoarthritis. Osteoarthritis is just one of many ailments th...

Presenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:PXS).

Ongoing studies of Cynata Therapeutics’ Cymerus stem cell products are beginning to reveal a wide range of commercial possibilities for the ASX-listed company’s cutting edge biotechnology that it is looking to apply to a multitude of ailmen...

ASX-listed Cynata Therapeutics, a Melbourne-based, clinical-stage biotech company specialising in cell therapeutics, has produced trial results confirming the initial success of its Cymerus mesenchymal stem cells, or “MSCs” ability to resto...

ShareCafeCynata Therapeutics – ShareCafe Hidden Gems Webinar Presentation   Presenter – Dr. Ross Macdonald – CEO & MD – Cynata is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of th...

ShareCafeHidden Gems Webinar Recap – OSL, MDC, CYP, GSS   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Oncosil Medical (ASX:OSL), Medlab Clinical...

Canary Capital is making a huge bet on a company that thinks stem cells aren’t the future of medicine. The small- and micro-cap Sydney investment house has just finished a $10m capital raising for regenerative medicine company Exopharm, a M...

Australian company Cynata Therapeutics (ASX:CYP) says it has begun patient enrolment in its MEND (MEseNchymal coviD-19) trial.

The Cynata Therapeutics Ltd (ASX: CYP) share price leapt by as much as 14% this morning as patient enrolment begins on the company’s COVID-19 trial. Cynata is trialling the use of its Cymerus MSC technology in COVID-19 patients with respi...

While treatments for pain management per se may not receive as much attention as those related to cures for chronic diseases, every day there is a large universe of people who attempt to treat but mismanage agonising and debilitating condit...

By Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the d...

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Ross Macdonald, CEO of Cynata Thera...

Fortunes were to be made in ASX health stocks during March and April as investors looked for salvation from the COVID-19 pandemic fears rocking markets. However, once the two biggest health stocks Resmed (ASX:RMD) and CSL (ASX:CSL) are take...

In the last fortnight another two dozen directors of ASX small caps made trades above $100,000 and a number of them chipped into potash stocks. COVID-19 was the last thing potash stocks needed having been struggling prior to the pandemic. T...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies. However, use of the two most famous treatments to date — Gilead Sciences’ HIV drug remdesivir and US President Donald Trump’...

Biotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by repurposing its Cymerus mesenchymal stem cells (MSCs) products and research. In a statement to the market, Cynata said it had received ethic...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Our summary of Cynata Therapeutics Ltd's recent announcement What's happened? Cynata Therapeutics Ltd (ASX:CYP "Cynata") has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s propriet...

The COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand the last two months, up 36 per cent on the prior two months as many organisations deem the patient risk of exposure to be too high. Globally,...

Clinical-stage biotechnology company specialising in cell therapeutics Cynata Therapeutics (ASX:CYP) has provided an update on the planned clinical trials of its Cymerus mesenchymal stem cell products for osteoarthritis and critical...

The S&P/ASX 200 index (ASX: XJO) has followed the lead of U.S. markets and is trading notably lower again on Friday. At the time of writing the benchmark index is down 6.7% to 4,947 points. Four shares that have managed to avoid the se...

Cynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceutical companies and other parties regarding using its Cymerus mesenchymal stem cell (MSC) platform to treat COVID-19 patients that develop sev...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

ShareCafeAll The Dope On Emerald Clinics’ Limp Debut Having been long on promises but short on deliverables, the ASX listed cannabis sector is taking an evolutionary step from growing the stuff to proving that pot is indeed the healing herb...

The Australian clinical-stage stem cell and regenerative medicine company is focused on the development of stem cell platform technology for commercial production with the help of pharmaceutical partner Fuji Film.

Cynata Therapeutics (CYP) has received a notice of allowance from the Israel Patent Office for a patent application for its Cymerus stem cell technology A notice of allowance is a good indicator that the applicant’s product will be issued...

Cynata Therapeutics (CYP) has released its December 2019 quarterly report, primarily outlining positive operations Highlights for the biotech company include planning multiple Phase 2 clinical trials and receiving a notice of allowance fro...

Cynata’s managing director Dr Ross Macdonald will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

With triple the number of sepsis cases in Australia, small cap biotech company Cynata Therapeutics (ASX:CYP) hopes to wage a new war on blood infections. Last Friday the world learned blood infections were on the rise, with researchers show...

In a preclinical study in a mouse model of CLI, treatment with Cymerus MSCs led to significantly higher blood flow in the ischaemic limb and protection against muscle damage, fibrosis and limb loss.

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

Cynata Therapeutics (CYP) has received approval from the U.K. Medicines and Healthcare products Regulatory Agency to begin the phase 2 trial of CYP-002 This product will be used in patients with reduced blood flow in their limbs The comp...

14 Jan 2020 - Cell therapeutics company Cyanata (ASX:CYP) has received the greenlight from British medical authority MHRA to begin the company’s Phase 2 clinical trial of its CYP-0…

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small cap health stocks, 47 saw their share prices fall, 67 improved and 22 were flat. >> Scroll down for a table showing the performance of s...

The Cynata Therapeutics Ltd (ASX: CYP) share price was on form on Tuesday. The clinical-stage biotechnology company’s shares finished the day 5% higher at $1.20. This stretches its year to date gain to almost 15%. Why did the Cynata share...

Cynata Therapeutics (CYP) has received a research and development tax incentive of nearly $2 million for the 2018-2019 financial year This refund increases the company’s cash position which stood at $9.2 million at the end of the Septembe...

07 Jan 2020 - Biotechnology company Cynata Therapeutics (ASX:CYP) has received an almost $2 million R&D Tax Incentive Refund for the 2018/2019 financial year.

The Cynata Therapeutics Ltd (ASX: CYP) share price has jumped 9.8% after opening today, with CYP shares trading at $1.11 at the time of writing. Cynata shares had closed at $1.02 yesterday before opening at $1.10 this morning and moving hi...

Pre-clinical studies using Cynata Therapeutics’ (ASX: CYP) Cymerus mesenchymal stem cells in a sepsis model have achieved positive results. In a pre-clinical model of severe pneumonia-induced sepsis, Cynata’s Cymerus treatment had several p...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

The company is an Australian clinical-stage stem cell and regenerative medicine corporation focused on the development of therapies based on Cymerus – a therapeutic stem cell platform technology.

Health care system of Australia is considered as one of the best, globally, as it delivers safe and affordable health care solutions and services to the citizens. Health care sector in Australia comprises of medical service, medical insuran...

The Cynata Therapeutics Ltd (ASX: CYP) share price has come under pressure on Thursday. Its shares were down as much as 15% at one stage before rebounding slightly. Unfortunately, this sizeable decline has wiped out the majority of Cynata’...

Avecho Biotechnology (ASX:AVE), the company formerly known as Phosphagenics, announced that its Japanese partner is pulling support after three years of research. Avecho has a patented drug delivery system called targeted penetration matrix...